Genentech, a member of the Roche Group (SIX ... During an AIS, brain damage occurs and progresses rapidly, meaning every moment without intervention leads to irreversible loss of nervous tissue ...

meaning they have no known function but could turn out to be useful drug targets. Genentech will be responsible for developing and marketing any new medicines that arise for the alliance and will ...

Roche Holding AG scrapped long-held global diversity targets for its leadership, showing how pressure from the Trump administration is causing companies to back away from DEI policies outside the US.

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. This approval of ...

Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label expansion for clot-dissolving agent TNKase (tenecteplase) – the first ...

Genentech disclosed in regulatory filings this ... according to a LinkedIn estimate, meaning that nearly 200 positions could ...

A four-year battle over one of the most ubiquitous patents in biotech ended with the US Patent and Trademark Office (USPTO) coming down on Genentech's side. The decision, reached in February ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental ...

Genentech, a member of the Roche Group, has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of ...

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus.